Healthequity Research and Development Expense Trend from 2010 to 2022

HQY
 Stock
  

USD 66.81  0.06  0.09%   

Healthequity Research and Development Expense yearly trend continues to be fairly stable with very little volatility. Research and Development Expense is likely to outpace its year average in 2022. During the period from 2010 to 2022, Healthequity Research and Development Expense regression line of anual values had slope of 13,803,917 and arithmetic mean of  50,885,806. Healthequity Direct Expenses is fairly stable at the moment as compared to the past year. Healthequity reported Direct Expenses of 286.41 Million in 2021. Cost of Revenue is likely to rise to about 359.1 M in 2022, whereas Consolidated Income is likely to drop (45.5 M) in 2022.
  
Refresh
Check Healthequity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Healthequity main balance sheet or income statement drivers, such as Direct Expenses of 309 M, Cost of Revenue of 359.1 M or Gross Profit of 457.2 M, as well as many exotic indicators such as Interest Coverage of 1.19, Long Term Debt to Equity of 0.93 or PPandE Turnover of 34.47. Healthequity financial statements analysis is a perfect complement when working with Healthequity Valuation or Volatility modules. It can also supplement various Healthequity Technical models. Please check the analysis of Healthequity Correlation against competitors.

Healthequity Quarterly Research and Development Expense

45.18 Million

Share

Healthequity Research and Development Expense Breakdown

Showing smoothed Research and Development Expense of Healthequity with missing and latest data points interpolated. A component of Operating Expenses representing the aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service.Healthequity's Research and Development Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Healthequity's overall financial position and show how it may be relating to other accounts over time.
Research and Development Expense10 Years Trend
Increasing
Slightly volatile
 Research and Development Expense 
Share
      Timeline 

Healthequity Research and Development Expense Regression Statistics

Arithmetic Mean 50,885,806
Geometric Mean 23,090,912
Coefficient Of Variation 119.68
Mean Deviation 50,152,808
Median 22,375,000
Standard Deviation 60,897,872
Range 165,558,474
R-Value 0.88
R-Squared 0.78
Significance 0.00006422
Slope 13,803,917

Healthequity Research and Development Expense History

20137.1 M
201410.5 M
201516.8 M
201622.4 M
201727.4 M
201835.1 M
201977.6 M
2020124.8 M
2021157.4 M
2022169.8 M

About Healthequity Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Healthequity income statement, its balance sheet, and the statement of cash flows. Healthequity investors use historical funamental indicators, such as Healthequity's Research and Development Expense, to determine how well the company is positioned to perform in the future. Although Healthequity investors may use each financial statement separately, they are all related. The changes in Healthequity's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Healthequity's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Healthequity Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Healthequity. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Research and Development Expense157.4 M169.8 M
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company was incorporated in 2002 and is headquartered in Draper, Utah. Healthequity operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 3688 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Healthequity without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Healthequity using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Healthequity Correlation against competitors. Note that the Healthequity information on this page should be used as a complementary analysis to other Healthequity's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Healthequity Stock analysis

When running Healthequity price analysis, check to measure Healthequity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healthequity is operating at the current time. Most of Healthequity's value examination focuses on studying past and present price action to predict the probability of Healthequity's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Healthequity's price. Additionally, you may evaluate how the addition of Healthequity to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Healthequity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Healthequity. If investors know Healthequity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Healthequity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.96
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
0.12
Return On Assets
0.0059
Return On Equity
-0.0299
The market value of Healthequity is measured differently than its book value, which is the value of Healthequity that is recorded on the company's balance sheet. Investors also form their own opinion of Healthequity's value that differs from its market value or its book value, called intrinsic value, which is Healthequity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Healthequity's market value can be influenced by many factors that don't directly affect Healthequity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine Healthequity value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.